Movement Alert｜Agilent Technologies Rises 5.12% in Regular Trading, Completes Acquisition of Biocare Medical to Expand Clinical Diagnostics

Market Focus

06/25

On June 25, Agilent Technologies rose 5.12% in regular trading, trading at $138.615/share, with turnover of $60.52 million. The rally was driven by the company's announcement that it has completed its acquisition of Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners.

Following the transaction, Biocare Medical has been formally integrated into Agilent's Life Sciences and Diagnostics Markets Group. The acquisition is viewed as a strategic expansion of the company's pathology product portfolio, marking a critical step forward in digital pathology platforms and high-precision cancer staining diagnostics. Management maintains an optimistic outlook on integration prospects from a financial perspective.

The move comes amid broader positive momentum for Agilent, which recently reported fiscal Q2 adjusted EPS of $1.49, beating estimates of $1.41 by 5.67%, while revenue of $1.835 billion also topped consensus. The company raised full-year guidance to adjusted EPS of $6.00-$6.10. Additionally, Barclays raised its price target to $150 from $145, maintaining an Overweight rating.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1137359912"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137359912\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137359912?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137359912","market":"us","top_or_hot":-1,"title":"Movement Alert｜Agilent Technologies Rises 5.12% in Regular Trading, Completes Acquisition of Biocare Medical to Expand Clinical Diagnostics","media":"Market Focus","content":"<p><p>On June 25, Agilent Technologies rose 5.12% in regular trading, trading at $138.615/share, with turnover of $60.52 million. The rally was driven by the company's announcement that it has completed its acquisition of Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners.</p><p>Following the transaction, Biocare Medical has been formally integrated into Agilent's Life Sciences and Diagnostics Markets Group. The acquisition is viewed as a strategic expansion of the company's pathology product portfolio, marking a critical step forward in digital pathology platforms and high-precision cancer staining diagnostics. Management maintains an optimistic outlook on integration prospects from a financial perspective.</p><p>The move comes amid broader positive momentum for Agilent, which recently reported fiscal Q2 adjusted EPS of $1.49, beating estimates of $1.41 by 5.67%, while revenue of $1.835 billion also topped consensus. The company raised full-year guidance to adjusted EPS of $6.00-$6.10. Additionally, Barclays raised its price target to $150 from $145, maintaining an Overweight rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Agilent Technologies Rises 5.12% in Regular Trading, Completes Acquisition of Biocare Medical to Expand Clinical Diagnostics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Agilent Technologies Rises 5.12% in Regular Trading, Completes Acquisition of Biocare Medical to Expand Clinical Diagnostics\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-06-25 22:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On June 25, Agilent Technologies rose 5.12% in regular trading, trading at $138.615/share, with turnover of $60.52 million. The rally was driven by the company's announcement that it has completed its acquisition of Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners.</p><p>Following the transaction, Biocare Medical has been formally integrated into Agilent's Life Sciences and Diagnostics Markets Group. The acquisition is viewed as a strategic expansion of the company's pathology product portfolio, marking a critical step forward in digital pathology platforms and high-precision cancer staining diagnostics. Management maintains an optimistic outlook on integration prospects from a financial perspective.</p><p>The move comes amid broader positive momentum for Agilent, which recently reported fiscal Q2 adjusted EPS of $1.49, beating estimates of $1.41 by 5.67%, while revenue of $1.835 billion also topped consensus. The company raised full-year guidance to adjusted EPS of $6.00-$6.10. Additionally, Barclays raised its price target to $150 from $145, maintaining an Overweight rating.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"A","symbol_name":"安捷倫科技","start_time":0,"source_url":"","article_id":"1137359912","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137359912","pubTimestamp":1782398267,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, Agilent Technologies rose 5.12% in regular trading, trading at $138.615/share, with turnover of $60.52 million. The rally was driven by the company's announcement that it has completed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"A":"安捷伦科技"},"translate_title":"动静提示|安捷伦科技常规交易涨5.12%完成收购Biocare Medical拓展临床诊断","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"A":1},"content_text":"On June 25, Agilent Technologies rose 5.12% in regular trading, trading at $138.615/share, with turnover of $60.52 million. The rally was driven by the company's announcement that it has completed its acquisition of Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners.Following the transaction, Biocare Medical has been formally integrated into Agilent's Life Sciences and Diagnostics Markets Group. The acquisition is viewed as a strategic expansion of the company's pathology product portfolio, marking a critical step forward in digital pathology platforms and high-precision cancer staining diagnostics. Management maintains an optimistic outlook on integration prospects from a financial perspective.The move comes amid broader positive momentum for Agilent, which recently reported fiscal Q2 adjusted EPS of $1.49, beating estimates of $1.41 by 5.67%, while revenue of $1.835 billion also topped consensus. The company raised full-year guidance to adjusted EPS of $6.00-$6.10. Additionally, Barclays raised its price target to $150 from $145, maintaining an Overweight rating.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}